- Company
- Sales of Actinum series have been sluggish
- by Nho, Byung Chul Dec 13, 2022 06:07am
- The Actinum series, once known as Takeda Pharmaceutical's signature mixed vitamin, is experiencing its biggest sales slump in more than seven years since its launch. According to drug distribution performance data, the performance of the Actinium series last year was 2.3 billion won, down 74% from 8.9 billion won in 2018. Between 2018 and 20
- Company
- “Tagrisso shows effect as 1st-line in the real world"
- by Dec 12, 2022 05:48am
- AstraZeneca’s 3rd generation EGFR mutation-positive non-small cell lung cancer (NSCLC) treatment ‘Tagrisso (osimertinib)’ has shown consistent effects with the clinical trial results in practice. In the real world, Tagrisso demonstrated excellent treatment effects even in patients with brain metastasis, poor systemic condition, or patients wi
- Company
- Nucala retries insurance benefits for the first time in five
- by Eo, Yun-Ho Dec 12, 2022 05:48am
- Nucala, a respiratory antibody drug, is seeking to register insurance benefits again. According to related industries, GSK Korea recently submitted an application for the salary of Nucala, a severe eosinophilic asthma treatment. It is the first re-challenge in about five years since the non-reimbursed decision of the Drug Benefit Evaluation C
- Company
- Daewoong suspends clinical trials of COVID-19 treatments
- by Kim, Jin-Gu Dec 12, 2022 05:47am
- All three clinical trials have been discontinued, and DWRX2003' has not progressed in domestic and foreign clinical trials. Daewoong decided to voluntarily stop the last clinical trial of DWJ1248, which was being developed as a treatment for severe COVID-19. Analysts say that Daewoong's COVID-19 project has also ended as all three clinical t
- Company
- GLP-1 Diabetic Trulicity's High Flux
- by Kim, Jin-Gu Dec 12, 2022 05:47am
- GLP-1 analog diabetes treatment Trulicity is on the rise. In the third quarter of last year, sales increased by 22% compared to the same period last year, continuing to grow. Attention is drawn to the competitive drug Ozempic. The pharmaceutical industry predicts that Ozempic will be a strong opponent of Trulicity. In the global market, Ozem
- Company
- “Immunotherapies take lead in liver cancer treatment"
- by Dec 9, 2022 06:04am
- “Immuno-oncology drugs have brought great advances in the treatment of unresectable advanced hepatocellular carcinoma. However, the unfortunate fact is that these are not well used in the field due to lack of later-line options.” Professor Joong-Won Park, Division of Gastroenterology, National Cancer Center Korea, said so to Dailypharm at t
- Company
- Ildong's new migraine drug Reyvow can be prescribed at gener
- by Eo, Yun-Ho Dec 9, 2022 06:04am
- According to related industries, Lilly and Ildong Pharmaceutical's Reyvow passed the Drug Commission (DC) of medical institutions such as Kangwon National University Hospital, Nowon-eulji Hospital, and Sinchon Severance Hospital, and advanced general hospitals such as Seoul National University Hospital, Asan Medical Center, and Seoul St. Mary
- Company
- Enhertu seeks approval as 2nd-line tx in breast cancer
- by Eo, Yun-Ho Dec 8, 2022 06:05am
- The antibody-drug conjugate anticancer drug ‘Enhertu’ is attempting to extend its indication to the second line in breast cancer. According to industry sources, the Ministry of Food and Drug Safety is currently reviewing whether to expand the indication for the ADC drug Enhertu (trastuzumab deruxtecan). Its approval is expected in Q1
- Company
- AbTis contracts ADC technology cooperation/ world's #1
- by Dec 8, 2022 06:05am
- ApTis, a company specializing in antibody-drug conjugate (ADC) development, announced on the 7th that it has signed a technology cooperation contract for antibody-drug combination platform for new drug development with global CDMO company Ron. With this cooperation, AbTis' "AppClick" platform technology will be included in Lonza's customi
- Company
- The power of FDA-approved new drugs
- by Chon, Seung-Hyun Dec 8, 2022 06:05am
- SK Biopharm announced on the 6th that it won the "Tower of Exporting $100 million" at the 59th Trade Day ceremony held at COEX in Gangnam-gu, Seoul on the 5th. SK Biopharm's independently developed innovative new drug, Cenobamate, surpassed $100 million in exports to the U.S. and Europe from July 1, 2021, to June 30, 2022. This is the first t
